Reaction
Plasmablastic Lymphoma reporting signals
As of the last recalculation, Plasmablastic Lymphoma appears in 352 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is SIROLIMUS (PRR 73.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Sirolimus | 16 | 73.5 | 73.6 |
| Dolutegravir Sodium | 10 | 67.4 | 67.5 |
| Adalimumab-Fkjp | 46 | 67.4 | 67.5 |
| Adalimumab-Aaty | 46 | 66.0 | 66.0 |
| Adalimumab-Adaz | 46 | 59.1 | 59.2 |
| Rifampicin | 8 | 47.8 | 47.9 |
| Tofacitinib Citrate | 10 | 46.4 | 46.4 |
| Daptomycin | 7 | 45.8 | 45.8 |
| Bortezomib | 56 | 43.8 | 43.9 |
| Doxorubicin | 55 | 43.1 | 43.1 |
| Daratumumab | 23 | 36.4 | 36.4 |
| Raltegravir | 9 | 33.1 | 33.1 |
| Vincristine Sulfate | 15 | 31.6 | 31.6 |
| Etoposide | 33 | 29.2 | 29.2 |
| Ifosfamide | 10 | 28.3 | 28.3 |